BioCentury on BioBusiness,
Product Discovery & Development
Table: Checking up on melanoma
Back to the parent article
Monday, June 10, 2013
Phase I proof-of-concept data presented at last week's
American Society of Clinical Oncology
meeting in Chicago suggest the next wave of immunotherapies in melanoma could
generate better tumor responses than Yervoy ipilimumab with the same or better
safety profile. Yervoy is a first-generation mAb immune checkpoint inhibitor
that targets CTLA-4 (CD152). It was approved in 2011 and is marketed by Bristol-Myers
Squibb Co. (NYSE:BMY) to treat unresectable or metastatic melanoma. At ASCO,
new checkpoint inhibitor mAbs from BMS,
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]